Evotec AG And Spero Extend Collaboration To Develop Novel Antibacterials

HAMBURG, Deutschland--(BUSINESS WIRE)--Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced an extension of an existing collaboration with Spero Therapeutics ("Spero"), based in Cambridge, Massachusetts, aimed at discovering and developing new and ground-breaking therapeutics for Gram-negative bacteria to treat serious infections and address the growing threat to global public health resulting from antibiotic resistance.